R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1 acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.
1. A method for preparing L-aspartate of a quinolone antimicrobial agent, comprising reacting the quinolone antimicrobial agent with L-aspartic acid in an inert organic solvent that comprises ethyl acetate, methanol, ethanol, isopropanol, acetone, acetonitrile, hexane, isopropyl ether, or water, wherein the quinolone antimicrobial agent comprises norfloxacin, ofloxacin, ciprofloxacin, sparfloxacin, or combinations thereof, provided that about 0.9 to about 2.5 equivalent weight of the L-aspartic acid is added to about 1 equivalent weight of the quinolone antimicrobial agent.
2. The method of claim 1 , provided that the quinolone antimicrobial agent is active against Gram-positive bacteria, Gram-negative bacteria, or methicillin resistant bacteria.
3. A method of improving water solubility of a quinolone antimicrobial agent, comprising converting the quinolone antimicrobial agent into a pharmaceutically acceptable L-aspartate salt in an inert organic solvent that comprises ethyl acetate, methanol, ethanol, isopropanol, acetone, acetonitrile, hexane, isopropyl ether, or water, wherein the quinolone antimicrobial agent comprises norfloxacin, ofloxacin, ciprofloxacin, sparfloxacin, or combinations thereof, provided that about 0.9 to about 2.5 equivalent weight of L-aspartic acid is added to about 1 equivalent weight of the quinolone antimicrobial agent.
4. The method of claim 3 , provided that the salt has water solubility of at least about 100 mg/ml at room temperature.
5. The pharmaceutically acceptable salt of claim 3 , provided that the salt has water solubility of at least about 118 mg/ml at room temperature.
6. The method of claim 3 , provided that the salt has a greater mean oral bioavailability than a hydrochloric acid salt of the quinolone antimicrobial agent.
7. The method of claim 6 , provided that the salt has at least about a 30% greater mean oral bioavailability than a hydrochloric acid of the quinolone antimicrobial agent.
8. The method of claim 3 , provided that the quinolone antimicrobial agent is active against Gram-positive bacteria, Gram-negative bacteria, or methicillin resistant bacteria.
9. The method of claim 1 , provided that the quinolone antimicrobial agent comprises norfloxacin.
10. The method of claim 1 , provided that the quinolone antimicrobial agent comprises ofloxacin.
11. The method of claim 1 , provided that the quinolone antimicrobial agent comprises ciprofloxacin.
12. The method of claim 1 , provided that the quinolone antimicrobial agent comprises sparfloxacin.
13. The method of claim 3 , provided that the quinolone antimicrobial agent comprises norfloxacin.
14. The method of claim 4 , provided that the quinolone antimicrobial agent comprises ofloxacin.
15. The method of claim 5 , provided that the quinolone antimicrobial agent comprises ciprofloxacin.
16. The method of claim 6 , provided that the quinolone antimicrobial agent comprises sparfloxacin.